Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.
Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.
However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.
- This report provides in-depth analysis of the hepatitis drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 – 2033, considering 2025 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global hepatitis drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts
-
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
-
- Hepatitis B
- Hepatitis C
- Others
-
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Merck & Co. Inc.
- Gilead Sciences Inc.
- AbbVie Inc.
- Bristol Myers Squibb Company
- Hoffmann-La Roche Ltd.
- LAURUS Labs, Zydus Cadila
- Hetero Healthcare Limited
- GlaxoSmithKline PLC.
- Cipla Inc
